Literature DB >> 10592094

Inflammatory mechanisms in neonatal chronic lung disease.

C P Speer1.   

Abstract

UNLABELLED: Chronic lung disease (CLD) of preterm infants has a multifactorial aetiology. Oxygen toxicity, mechanical injury (barotrauma), volutrauma as well as prenatal and postnatal infections most likely contribute to pulmonary injury in the immature lung of preterm infants. There is sufficient evidence that respiratory distress syndrome and CLD are associated with a significant inflammatory response of the airways and the interstitium of the lungs; besides neutrophils, alveolar and interstitial macrophages immunoreactive for tumour necrosis factor-alpha (TNF-alpha) are found in large numbers. Phagocyte influx is possibly mediated by chemotactic and chemokinetic factors present in the broncho-alveolar secretions: interleukin-8, leukotriene B(4), C5a, elastin fragments, macrophage-inflammatory protein-1alpha and other chemokines. Increased concentrations of soluble selectins and intercellular adhesion molecule-1 in broncho-alveolar secretions and the serum of infants with CLD possibly reflect neutrophil diapedesis. Lipid mediators including leukotrienes, prostacyclin, platelet activating and other mediators such as the pro-inflammatory cytokines TNF-alpha, interleukin-1 and -6, exert various effects on the airways and the vascular system by increasing the microvascular permeability which is one of the most important pathophysiological factors of early CLD. Pulmonary cells of preterm infants may be unable to downregulate inflammation through the expression of the anti-inflammatory cytokine interleukin-10. Inflammatory cells can cause severe lung damage by release of potent proteases (elastase), cytokines and by generation of toxic oxygen radicals (O(2)-, (*)OH). The presence of free elastase activity and the protease-antiprotease imbalance has been well documented. In fact, increased concentrations of products of elastolytic fibre degradation and of oxygen radical mediated lipid peroxidation were detected in infants with CLD.
CONCLUSION: The complex interaction between mediators of inflammation and fibrosis has still to be defined. Moreover, the possible interference of inflammation with postnatal lung development especially with the alveolarization process has not been evaluated yet.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10592094     DOI: 10.1007/pl00014314

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  14 in total

Review 1.  Inflammatory mediators in the immunobiology of bronchopulmonary dysplasia.

Authors:  Rita M Ryan; Qadeer Ahmed; Satyan Lakshminrusimha
Journal:  Clin Rev Allergy Immunol       Date:  2008-04       Impact factor: 8.667

2.  HFOV in premature neonates: effects on pulmonary mechanics and epithelial lining fluid cytokines. A randomized controlled trial.

Authors:  Giovanni Vento; Piero G Matassa; Franco Ameglio; Ettore Capoluongo; Enrico Zecca; Luca Tortorolo; Mara Martelli; Costantino Romagnoli
Journal:  Intensive Care Med       Date:  2005-02-17       Impact factor: 17.440

3.  5-Lipoxygenase-activating protein (FLAP) inhibitor MK-0591 prevents aberrant alveolarization in newborn mice exposed to 85% oxygen in a dose- and time-dependent manner.

Authors:  Min Soo Park; Myung Hyun Sohn; Kyu-Earn Kim; Moon Sung Park; Ran Namgung; Chul Lee
Journal:  Lung       Date:  2010-11-05       Impact factor: 2.584

4.  Foxm1 regulates resolution of hyperoxic lung injury in newborns.

Authors:  Hongping Xia; Xiaomeng Ren; Craig S Bolte; Vladimir Ustiyan; Yufang Zhang; Tushar A Shah; Tanya V Kalin; Jeffrey A Whitsett; Vladimir V Kalinichenko
Journal:  Am J Respir Cell Mol Biol       Date:  2015-05       Impact factor: 6.914

5.  Enteral lactoferrin for the treatment of sepsis and necrotizing enterocolitis in neonates.

Authors:  Mohan Pammi; Steven A Abrams
Journal:  Cochrane Database Syst Rev       Date:  2019-05-11

Review 6.  Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants.

Authors:  Mohan Pammi; Gautham Suresh
Journal:  Cochrane Database Syst Rev       Date:  2017-06-28

7.  Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells.

Authors:  T Ichiyama; M Nishikawa; T Yoshitomi; S Hasegawa; T Matsubara; T Hayashi; S Furukawa
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 8.  Considerations in the pharmacologic treatment and prevention of neonatal sepsis.

Authors:  Chris Stockmann; Michael G Spigarelli; Sarah C Campbell; Jonathan E Constance; Joshua D Courter; Emily A Thorell; Jared Olson; Catherine M T Sherwin
Journal:  Paediatr Drugs       Date:  2014-02       Impact factor: 3.022

9.  The effect of fetal stabilization using morphine hydrochloride on neonatal rats.

Authors:  Toru Uesugi; Kouji Masumoto; Kouji Nagata; Tomoaki Taguchi; Sachiyo Suita
Journal:  Pediatr Surg Int       Date:  2007-10       Impact factor: 1.827

Review 10.  The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema.

Authors:  H Clark; K Reid
Journal:  Arch Dis Child       Date:  2003-11       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.